Application In Synthesis of 1-Phenylurea. Grossi, F; Genova, C; Crino, L; Delmonte, A; Turci, D; Signorelli, D; Passaro, A; Parra, HS; Catino, A; Landi, L; Gelsomino, F; Tiseo, M; Puppo, G; Roila, F; Ricciardi, S; Tonini, G; Cognetti, F; Toschi, L; Tassinari, D; Scoppola, A; Giannarelli, D; Cortesi, E in [Grossi, Francesco] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Med Oncol Unit, Milan, Italy; [Genova, Carlo] IRCCS Osped Policlin San Martino, Lung Canc Unit, Genoa, Italy; [Crino, Lucio; Delmonte, Angelo] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Dept Med Oncol, Meldola, Italy; [Turci, Daniele] Osped S Maria Delle Croci, Med Oncol Unit, Ravenna, Italy; [Signorelli, Diego] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy; [Passaro, Antonio] European Inst Oncol IRCCS, IEO, Div Thorac Oncol, Milan, Italy; [Parra, Hector Soto] Azienda Osped Univ AOU Policlin Vittorio Emanuele, Dept Oncol, Catania, Italy; [Catino, Annamaria] IRCCS Ist Tumori Giovanni Paolo II, Med Oncol Unit, Patol Torac, Bari, Italy; [Landi, Lorenza] AUSL Romagna, Dept Hematol Oncol, Ravenna, Italy; [Gelsomino, Francesco] AOU Policlin St Orsola Malpighi, Oncol Unit, Bologna, Italy; [Tiseo, Marcello] Univ Parma, Dept Med & Surg, Parma, Italy; [Tiseo, Marcello] Azienda Osped Univ Parma, Oncol Med, Parma, Italy; [Puppo, Gianfranco] Osped Macerata, Pulmonol Unit, Macerata, Italy; [Roila, Fausto] Osped S Maria Misericordia, Med Oncol Unit, Perugia, Italy; [Ricciardi, Serena] Azienda Osped San Camillo Forlanini, Pulm Oncol Unit, Rome, Italy; [Tonini, Giuseppe] Univ Campus Biomed, Dept Oncol, Rome, Italy; [Cognetti, Francesco] Univ Roma La Sapienza, Ist Nazl Tumori Regina Elena, Med Oncol Unit, Rome, Italy; [Toschi, Luca] IRCCS Ist Clin Humanitas, Dept Hematol Oncol, Rozzano, Italy; [Tassinari, Davide] AUSL Romagna, Oncol Unit, Rimini, Italy; [Scoppola, Alessandro] Ist Dermopat Immacolata, Dept Med Oncol, Rome, Italy; [Giannarelli, Diana] Ist Nazl Tumori Regina Elena, BIostat, Rome, Italy; [Cortesi, Enrico] Policlin Umberto 1, Oncol Unit, Rome, Italy published Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer in 2019.0, Cited 19.0. The Name is 1-Phenylurea. Through research, I have a further understanding and discovery of 64-10-8.
Background: Nivolumab was the first immune checkpoint inhibitor approved for previously treated advanced nonesmall cell lung cancer (NSCLC). Before its introduction in the market, nivolumab was made available to NSCLC patients through an expanded access program (EAP). Here we present the Italian cohort of patients with non-squamous NSCLC enrolled in a worldwide nivolumab EAP, with subgroup analyses involving elderly patients, patients with central nervous system (CNS) metastases and patients receiving nivolumab beyond progression. Methods: Pretreated patients with advanced non-squamous NSCLC received nivolumab at 3 mg/kg every 2 weeks up to 24 months. Efficacy data (investigator-assessed tumour response, progression date and survival) and safety data were collected. Findings: 1588 patients were treated across 153 Italian centres. Overall response rate and disease control rate were 18% and 44%, respectively; median overall survival (OS) was 11.3 months (95% CI: 10.2-12.4). Elderly patients (>= 70 n = 522; >= 75 n = 232) achieved outcomes similar to the global study population; patients with CNS metastases (n = 409) had an OS of 8.6 months (95% CI: 6.4-10.8), and a 1-year OS rate of 43%. Nivolumab was administered beyond progression to 276 patients (26%), 57 of whom achieved subsequent disease control; the median OS of patients receiving nivolumab beyond progression was 16.2 months (95% CI: 14.0-18.4), while 1-year OS rate was 62%. Interpretation: To date, this is the largest clinical experience with nivolumab in a real-world setting. Our data support its use in clinical practice for pretreated non-squamous NSCLC, including patients with older age or CNS metastases. (C) 2019 Elsevier Ltd. All rights reserved.
Welcome to talk about 64-10-8, If you have any questions, you can contact Grossi, F; Genova, C; Crino, L; Delmonte, A; Turci, D; Signorelli, D; Passaro, A; Parra, HS; Catino, A; Landi, L; Gelsomino, F; Tiseo, M; Puppo, G; Roila, F; Ricciardi, S; Tonini, G; Cognetti, F; Toschi, L; Tassinari, D; Scoppola, A; Giannarelli, D; Cortesi, E or send Email.. Application In Synthesis of 1-Phenylurea
Reference:
Thiomorpholine – Wikipedia,
,Thiomorpholine | C4H9NS – PubChem